Zepatier (elbasvir and grazoprevir)
Share
Follow Us
What is Zepatier?
On January 28, 2016 the U.S. Food and Drug Administration approved the prescription medication Zepatier™ (elbasvir and grazoprevir). Elbasvir is a hepatitis C virus (HCV) NS5A inhibitor while grazoprevir is an HCVNS3/4A protease inhibitor. This combination is indicated with or without ribavirin for the treatment of HCV in adult patients with genotype 1 or 4 infections.
The active ingredients of Zepatier are 50 mg elbasvir and 100 mg grazoprevir.
Last Updated: February 2016
"Highlights of Prescribing Information." Merck.com. Merck Sharp & Dohme Corp., http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Retrieved February 1, 2016.
"Patient Information: Zepatier™." Merck.com. Merck Sharp & Dohme Corp., http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_ppi.pdf. Retrieved February 1, 2016.
"Zepatier Multiuse Savings Coupon." Activatethecard.com. Merck Sharp & Dohme Corp., https://www.activatethecard.com/7208/#. Retrieved February 1, 2016.
"Zepatier (Elbasvir and Grazoprevir) Official Website." Zepatier.com. Merck Sharp & Dohme Corp., https://www.zepatier.com/. Retrieved February 1, 2016.
